Gwaje-gwaje na asibiti sun tabbatar da cewa yawancin allurai naSemaglutidezai iya a amince da yadda ya kamata taimaka manya tare da kiba cimma gagarumin nauyi rage nauyi. Wannan binciken yana ba da sabuwar hanyar warkewa ga karuwar cutar kiba a duniya.
Fage
Semaglutide shine aGLP-1 agonist mai karɓaasali an haɓaka don sarrafa glucose na jini a cikin nau'in ciwon sukari na 2. A cikin 'yan shekarun nan, masu bincike sun gano rawar da ya taka a cikitsarin cin abinci da sarrafa nauyi. Ta hanyar kwaikwayon aikin GLP-1, Semaglutide yana rage ci kuma yana jinkirta zubar da ciki, a ƙarshe yana rage cin abinci.
Bayanan asibiti
Tebur da ke ƙasa yana taƙaita sakamakon asarar nauyi da aka lura tare da allurai daban-daban na Semaglutide a cikin gwaji na asibiti:
Kashi (mg/week) | Matsakaicin Rage Nauyi (%) | Mahalarta (n) |
---|---|---|
1.0 | 6% | 300 |
2.4 | 12% | 500 |
5.0 | 15% | 450 |
Binciken Bayanai
-
Tasirin dogara kashi: Daga 1mg zuwa 5mg, asarar nauyi ya karu a hankali.
-
Ma'auni mafi kyau: 2.4mg / mako kashi ya nuna tasiri mai mahimmanci na asarar nauyi (12%) kuma yana da mafi yawan ƙungiyar mahalarta, yana nuna cewa yana iya zama mafi yawan shawarar da aka ba da shawarar a cikin aikin asibiti.
-
Tsaro mai girma: Matsakaicin 5mg bai haifar da mummunan al'amuran da suka faru ba, yana nuna cewa mafi girma allurai na iya ƙara haɓaka inganci a ƙarƙashin yanayin tsaro mai sarrafawa.
Tsarin Trend
Hoto mai zuwa yana kwatanta tasirin allurai daban-daban na Semaglutide akan rage nauyi:
Kammalawa
A matsayin sabon magani na asarar nauyi, Semaglutide yana nuna bayyanannetasirin rage nauyi mai dogaro da kashia gwaji na asibiti. Tare da karuwar allurai, marasa lafiya sun sami asarar nauyi mafi girma. A nan gaba, ana tsammanin Semaglutide zai zama ginshiƙi a cikin jiyya na kiba, yana ba wa likitocin ƙarin zaɓuɓɓuka don keɓaɓɓen magani.
Lokacin aikawa: Satumba-17-2025